European Hospitals Face Growing Threat From Antibiotic Resistant Klebsiella Pneumoniae Bacteria
The European Centre for Disease Prevention and Control issued a warning regarding the rapid spread of Klebsiella pneumoniae in European hospitals across the continent. Some strains of Klebsiella pneumoniae have become resistant to nearly all available antibiotics, including new drugs developed for treatment. This dangerous bacterium can cause severe infections such as pneumonia, urinary tract infections, and sepsis in vulnerable patients. The European Centre for Disease Prevention and Control monitors these trends closely to protect public health across member states.
Growing Infection Threat
The bacterium poses a significant danger to hospitalized patients, post-operative individuals, and those with weakened immune systems. The infection can persist in the human body for years without causing any noticeable symptoms in the infected person. The mortality rate associated with these severe Klebsiella pneumoniae infections typically ranges between 40% and 70% for affected patients. This high mortality rate underscores the severity of the ongoing public health crisis across Europe.
Rising Infection Rates
The number of bloodstream infections caused by treatment-resistant Klebsiella pneumoniae increased by 72% in the European Union between 2019 and 2025. This substantial increase is significantly higher than the 5% reduction target set by the European Union for 2030. Christian Giske, the European Centre for Disease Prevention and Control director for antimicrobial resistance, stated that Klebsiella pneumoniae data represents the greatest concern among all superbacteria data collected in the last year. This alarming statistic shows that current infection control measures are struggling to keep pace with bacterial evolution.
Public Health Implications
Antimicrobial resistance causes approximately 35,000 deaths annually across the European Union, Iceland, and Norway. The European Centre for Disease Prevention and Control emphasizes that standard infection control measures may be insufficient against these highly resistant strains. Christian Giske also stated that for Europe, antimicrobial resistance represents a major threat to public health. The European Union is currently far from achieving its 2030 targets for reducing drug-resistant infections. The European Centre for Disease Prevention and Control recommends strict hygiene measures, including thorough surface disinfection and proper use of personal protective equipment to combat this growing threat.
Glossary
- European Union — The European Union is a political and economic union. It has 27 members. The European Union has grown in the last 50 years.
- Klebsiella pneumoniae — Klebsiella pneumoniae carbapenemase (KPC)-producing bacteria are a group of emerging highly drug-resistant Gram-negative bacilli. These bacteria cause infections associated with significant morbidity and mortality. Klebsiella pneumoniae includes numerous mechanisms for antibiotic resistance.
- European Centre for Disease Prevention and Control — The European Centre for Disease Prevention and Control is an agency of the European Union (EU). Its mission is to strengthen Europe's defences against infectious diseases. The centre covers a wide spectrum of activities such as surveillance, epidemic intelligence, response, scientific advice, microbiology, preparedness, public health training, international relations, health communication, and the scientific journal Eurosurveillance.
- antibiotics — Treatment of ARS is generally supportive care. This may include blood transfusions, antibiotics, colony-stimulating factors, or stem cell transplant. The former involves the possible use of antibiotics, blood products, colony stimulating factors, and stem cell transplant.
- pneumonia — The European Centre for Disease Prevention and Control issued a warning regarding the rapid spread of Klebsiella pneumoniae in European hospitals across the continent. This dangerous bacterium can cause severe infections such as pneumonia, urinary tract infections, and sepsis in vulnerable patients.
This article was written with AI assistance from multiple news reports and is reviewed by our editors under our editorial principles. Editorial Standards · Tips & Contact
Comments 0